Prognostic Effect of VEGF Gene Variants in Metastatic Non-small-cell Lung Cancer Patients

Overview

Journal Angiogenesis

Publisher Springer

Specialty Hematology

Date 2019 Apr 13

PMID 30977010

Citations 23

Authors

Ivana Sullivan

Pau Riera

Marta Andres

Albert Altes

Margarita Majem

Remei Blanco

Laia Capdevila

Andres Barba

Agusti Barnadas

Juliana Salazar

Affiliations

Soon will be listed here.

Abstract

Introduction: Clinical and pathological characteristics are still considered prognostic markers in metastatic non-small-cell lung cancer (NSCLC) patients but they cannot explain all interindividual variability. Tumoral angiogenesis mediated by the vascular endothelial growth factor (VEGF) is critical for the progression and metastasis of the disease. We aimed to investigate the prognostic role of genetic variants within the VEGF pathway in patients with metastatic NSCLC.

Materials And Methods: We prospectively included 170 patients with metastatic NSCLC treated with first-line platinum-based chemotherapy. A comprehensive panel of single-nucleotide polymorphisms (SNPs) in genes belonging to the VEGF pathway (VEGFA, VEGFR1/FLT1, VEGFR2/KDR, GRB2, ITGAV, KISS1, KRAS, PRKCE, HIF1α, MAP2K4, MAP2K6, and MAPK11) were genotyped in blood DNA samples. SNPs were evaluated for association with overall survival (OS) and progression-free survival (PFS).

Results: In multivariate analyses adjusted for patient characteristics, we found that VEGFA rs2010963 and VEGFR2 rs2071559 were significantly associated with OS [Hazard Ratio (HR) 0.7 (0.5-0.9); p = 0.026 and HR 1.5 (1.1-2.3); p = 0.025, respectively]. Additionally, ITGAV rs35251833 and MAPK11 rs2076139 were significantly associated with PFS [HR 2.5 (1.4-4.3; p = 0.002 and HR 0.6 (0.5-0.9); p = 0.013, respectively].

Conclusion: Our findings reinforce the potential clinical value of germline variants in VEGFA and VEGFR2 and show for the first time variants in ITGAV and MAPK11 as promising prognostic markers in metastatic NSCLC patients receiving platinum-based chemotherapy.

Citing Articles

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) rs2071559 Gene Polymorphism and the Risk of Gliomas: A Systematic Review and Meta-Analysis.

Prasetiyo P, Wahjoepramono E J Clin Med. 2024; 13(15).

PMID: 39124599 PMC: 11313419. DOI: 10.3390/jcm13154332.

Metabolic reprogramming-driven homologous recombination and TCA cycle dysregulation contribute to poor prognoses in lung adenocarcinoma.

Xu Z, He D, Huang L, Deng K, Jiang W, Qin J J Cell Mol Med. 2024; 28(11):e18406.

PMID: 38822457 PMC: 11142899. DOI: 10.1111/jcmm.18406.

Phosphorylated MAPK11 promotes the progression of clear cell renal cell carcinoma by maintaining RUNX2 protein abundance.

Song X, Dong C, Man X J Cell Mol Med. 2023; 27(17):2583-2593.

PMID: 37525479 PMC: 10468653. DOI: 10.1111/jcmm.17870.

MAPK11 (p38β) is a major determinant of cellular radiosensitivity by controlling ionizing radiation-associated senescence: An in vitro study.

Fernandez-Aroca D, Garcia-Flores N, Frost S, Jimenez-Suarez J, Rodriguez-Gonzalez A, Fernandez-Aroca P Clin Transl Radiat Oncol. 2023; 41:100649.

PMID: 37346275 PMC: 10279794. DOI: 10.1016/j.ctro.2023.100649.

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F Ther Adv Med Oncol. 2023; 14:17588359221141307.

PMID: 36601631 PMC: 9806434. DOI: 10.1177/17588359221141307.

References

Morgensztern D, Ng S, Gao F, Govindan R . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2009; 5(1):29-33. DOI: 10.1097/JTO.0b013e3181c5920c. View

Zhan P, Wang J, Lv X, Wang Q, Qiu L, Lin X . Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009; 4(9):1094-103. DOI: 10.1097/JTO.0b013e3181a97e31. View

Alevizakos M, Kaltsas S, Syrigos K . The VEGF pathway in lung cancer. Cancer Chemother Pharmacol. 2013; 72(6):1169-81. DOI: 10.1007/s00280-013-2298-3. View

Piperdi B, Merla A, Perez-Soler R . Targeting angiogenesis in squamous non-small cell lung cancer. Drugs. 2014; 74(4):403-13. PMC: 4014113. DOI: 10.1007/s40265-014-0182-z. View

Koukourakis M, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E . VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004; 46(3):293-8. DOI: 10.1016/j.lungcan.2004.04.037. View

Stevens A, Soden J, Brenchley P, Ralph S, Ray D . Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003; 63(4):812-6. View

Glubb D, Cerri E, Giese A, Zhang W, Mirza O, Thompson E . Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011; 17(16):5257-67. PMC: 3156871. DOI: 10.1158/1078-0432.CCR-11-0379. View

Maeda A, Nakata M, Yasuda K, Yukawa T, Saisho S, Okita R . Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis. Oncol Rep. 2012; 29(1):39-44. PMC: 3583591. DOI: 10.3892/or.2012.2075. View

Dong J, Dai J, Shu Y, Pan S, Xu L, Chen W . Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis. 2010; 31(6):1080-6. DOI: 10.1093/carcin/bgq079. View

10.

de Mello R, Ferreira M, Soares-Pires F, Costa S, Cunha J, Oliveira P . The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer. PLoS One. 2013; 8(9):e72373. PMC: 3765163. DOI: 10.1371/journal.pone.0072373. View

11.

Masago K, Fujita S, Kim Y, Hatachi Y, Fukuhara A, Nagai H . Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci. 2009; 100(10):1917-22. PMC: 11159069. DOI: 10.1111/j.1349-7006.2009.01253.x. View

12.

Chen N, Ma C, Zhao M, Zhang Y . Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer. Genet Mol Res. 2015; 14(4):16006-11. DOI: 10.4238/2015.December.7.13. View

13.

Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang L . Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010; 10:431. PMC: 2939547. DOI: 10.1186/1471-2407-10-431. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Riera P, Virgili A, Salazar J, Sebio A, Tobena M, Sullivan I . Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer. Pharmacogenomics J. 2017; 18(4):556-564. DOI: 10.1038/s41397-017-0009-x. View

16.

Sullivan I, Salazar J, Arqueros C, Andres M, Sebio A, Majem M . KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer. Clin Transl Oncol. 2017; 19(7):884-890. DOI: 10.1007/s12094-017-1620-7. View

17.

Glubb D, Pare-Brunet L, Jantus-Lewintre E, Jiang C, Crona D, Etheridge A . Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015; 10(7):1067-75. PMC: 4494119. DOI: 10.1097/JTO.0000000000000549. View

18.

Pare-Brunet L, Sebio A, Salazar J, Berenguer-Llergo A, Rio E, Barnadas A . Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Pharmacogenomics J. 2015; 15(5):397-404. DOI: 10.1038/tpj.2015.1. View

19.

Butkiewicz D, Krzesniak M, Drosik A, Giglok M, Gdowicz-Klosok A, Kosarewicz A . The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer. Int J Cancer. 2015; 137(10):2332-42. DOI: 10.1002/ijc.29605. View

20.

Uzunoglu F, Kaufmann C, Wikman H, Gungor C, Bohn B, Nentwich M . Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer. Ann Surg Oncol. 2012; 19(7):2159-68. DOI: 10.1245/s10434-012-2227-4. View